Clinical and Pharmacological Approaches to the Prescription of Centrally Acting Antihypertensive Drugs for Uncontrolled Arterial Hypertension
https://doi.org/10.20996/1819-6446-2020-10-18
Abstract
Episodes of rapid increase in blood pressure due to uncontrolled arterial hypertension, previously known as a hypertensive urgency, is common clinical condition which many of practicing physicians are encountered daily. As a rule, these conditions are not life-threatening, however they could lead to target-organs damage if not promptly relieved. Therefore, clear evidence-based recommendations of optimal antihypertensive drug administration in these situations would provide more safe and effective therapy. Despite that, definite expert consensus regarding optimal choice of antihypertensive drugs to manage these patients have not been reached so far. The aim of the current review was to assess the results obtained from clinical trials regarding the safety and efficacy of moxonidine for urgent hypertensive therapy in patients with uncontrolled arterial hypertension admitted to emergency healthcare units as well as in those at the prehospital stage. Performed literature-based analysis revealed enough evidences proving that moxonidine can be administered in a single dose of 0.4 mg as a drug of choice in situations where prompt and stable hypotensive effect is desired. Results of comparative studies designed to closely match real clinical settings indicate that more adequate and sustainable therapeutic effect is achieved after moxonidine administration in comparison to other frequently used antihypertensive drugs.
About the Authors
A. V. Strygin
Volgograd State Medical University
Russian Federation
Russian Federation
Andrey V. Strygin – MD, PhD, Head of Chair of Fundamental Medicine and Biology
Pavshikh Bortsov pl. 1, Volgograd, 400131
B. E. Tolkachev
Volgograd State Medical University;
Volgograd Medical Research Centre
Russian Federation
Russian Federation
Boris E. Tolkachev – MD, PhD, Associate Professor, Chair of Fundamental Medicine and Biology, Volgograd State Medical University; Senior Researcher, Laboratory of Clinical Pharmacology, Volgograd Medical Research Centre
Pavshikh Bortsov pl. 1, Volgograd, 400131
A. O. Strygina
Volgograd State Medical University
Russian Federation
Russian Federation
Anna О. Strygina – MD, Assistant, Chair of Immunology and Allergology
Pavshikh Bortsov pl. 1, Volgograd, 400131
A. M. Dotsenko
Volgograd State Medical University;
Volgograd Medical Research Centre
Russian Federation
Russian Federation
Anna М. Dotsenko – MD, Assistant, Chair of Fundamental Medicine and Biology, Volgograd State Medical University; Researcher, Laboratory of Clinical Pharmacology, Volgograd Medical Reseach Centre
Pavshikh Bortsov pl. 1, Volgograd, 400131
References
1. Tereshchenko S.N., Arutyunov G.P., Galyavich A.S., et al. Emergency care in case of a sudden pronounced individually significant increase in blood pressure without clinically obvious damage to target organs. Place of captopril. Conclusion of the Council of Experts of the RPO “Society of Specialists in Emergency Cardiology”. Russian Journal of Cardiology. 2020;25(2):103-10. (In Russ.) DOI:10.15829/1560-4071-2020-2-3748.
2. Order of the Ministry of Health of the Russian Federation dated July 5, 2016 No. 470n “On approval of the standard of emergency medical care for hypertension” [cited by Dec 10, 2018]. Available from: http://www.garant.ru/products/ipo/prime/doc/71348370/ (In Russ.)
3. Arterial hypertension in adults. Russian Clinical guidelines, 2020. [cited by Aug 11, 2020]. Available from: https://scardio.ru/content/Guidelines/Clinic_rek_AG_2020.pdf (In Russ.)
4. Chazova I.E., Zhernakova Y.V. Guidelines for diagnostics and treatment of hypertension 2018: European experts’ opinion. Systemic Hypertension. 2018;15(3):6-10 (In Russ.) DOI:10.26442/2075-082X_2018.3.6-10.
5. Edwards L.P., Brown-Bryan T.A., McLean L., Ernsberger P. Pharmacological properties of the central antihypertensive agent, moxonidine. Cardiovasc Ther. 2012;30(4):199-208. DOI:10.1111/j.1755-5922.2011.00268.x.
6. Tereshchenko S.N., Gaponova N.I., Abdrakhmanov V.R. A randomized, multicenter, controversial study of the efficacy of moхonidine in patients with uncomplicated hypertensive crisis (ABEC, AVES). Arterial Hypertension. 2011;4:316-24 (In Russ.)
7. Tereshchenko S.N., Gaponova N.I., Abdrakhmanov V.R., et al. Evaluation of the antihypertensive efficacy and safety of moxonidine in the treatment of uncomplicated hypertensive crisis. Systemic Hypertension. 2013;1:41-7 (In Russ.)
8. Ruksin V.V., Grishin O.V. Efficacy of captopril, moxonidineand their combinations with nifedipine in the non-threatening hypertension. Arterial Hypertension. 2010;19(1):60-5 (In Russ.)
9. Ruksin V.V., Grishin O.V. Moxonidine monotherapy and moxonidine plus furosemide combination therapy in hypertensive emergencies Arterial Hypertension. 2014;20(1):54-9 (In Russ.)
10. Ruksin V.V. Grishin O.V. Differentiated therapy of emergency conditions associated with increased blood pressure. Arterial Hypertension. 2010;16(3):292-8 (In Russ.)
11. Ruksin V.V., Grishin O.V. Emergency care for high blood pressure, not life-threatening. Kardiologiia. 2011;2:45-51 (In Russ.)
12. Ruksin V.V., Grishin O.V., Onuchin M.V. Comparison of the efficacy of preparations containing moxonidine during emergency antihypertensive therapy. Systemic Hypertension. 2015;2:8-12 (In Russ.)
13. Ruksin V.V., Grishin O.V. Hypertension Emergencies. Brands or generics? Skoraya Medizinskaya Pomosch. 2015;3(15):16-20 (In Russ.)
14. Ramenskaya G.V., Shokhin I.E., Gaponova N.I., Abdrakhmanov V.R. Assessment of in Vitro Comparative Dissolution Kinetics of Moxonidine Products as a Factor Potentially Determining Effectiveness of Antihypertensive Treatment. Rational Pharmacotherapy in Cardiology. 2018;14(6):951-7 (In Russ.) DOI:10.20996/1819-6446-2018-14-6-951-957.
Review
For citations:
Strygin A.V., Tolkachev B.E., Strygina A.O., Dotsenko A.M. Clinical and Pharmacological Approaches to the Prescription of Centrally Acting Antihypertensive Drugs for Uncontrolled Arterial Hypertension. Rational Pharmacotherapy in Cardiology. 2020;16(5):815-821. (In Russ.) https://doi.org/10.20996/1819-6446-2020-10-18
Views:
611
Email this article 